Loading…
Loading…
Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors?
BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding; Q2 2026 revenue reached $218.3M, with strong gross margins and positive cash flow independent of licensing receipts. The navenibart acquisition positions BCRX to capture injectable-preferring HAE patients, leveraging existing commercial infrastructure for operating leverage and customer retention.
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential.
Aurora Investment Counsel acquired a new stake in Haemonetics Corporation (NYSE: HAE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,501 shares of the medical instruments supplier's stock, valued at approximately $1,913,000. Aurora Investment Counsel owned about 0.06% of Haemonetics as
On August 18, 2026, Haemonetics Corp (HAE) shares rose 15.9%, bringing the current price to $104.65. This performance reflects a significant 52-week range, with
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.